Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
S-1/A - Picard Medical, Inc. (0002030617) (Filer)
S-8 - Picard Medical, Inc. (0002030617) (Filer)
8-K - Picard Medical, Inc. (0002030617) (Filer)
3 - Picard Medical, Inc. (0002030617) (Issuer)
TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company's fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks. During the session, Mr. Schuster will review preclinical experience with SynCardia's next-generation, fully implantable total artificial heart platform, Emperor. The presentation will include bench and acute in vivo data
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management. Anchored by a powerful patient survival story, the series highlights the real-world impact of the STAH on patients facing end stage heart failure. The discussion then turns to SynCardia System's / Picard Medical's
TUCSON, Ariz., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that on January 5, 2026 SynCardia entered into a development collaboration agreement (the "Agreement") with Hydrix Services Pty Ltd ("Hydrix"), a wholly owned subsidiary of Hydrix Limited (ASX: HYD), to commence an initial development phase for SynCardia's next-generation, fully implantable Total Artificial Heart (TAH) technology, known as the Emperor. As a fully implantable TAH, Emperor would eliminate the use of an external dr